Journal of Psychopharmacology最新文献

筛选
英文 中文
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain. 致幻剂作用下的半球退火和偏侧化(HEALS):一种关于大脑致幻剂作用的新假设。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2024-12-20 DOI: 10.1177/02698811241303599
Adam W Levin
{"title":"Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain.","authors":"Adam W Levin","doi":"10.1177/02698811241303599","DOIUrl":"10.1177/02698811241303599","url":null,"abstract":"<p><p>Current models of psychedelic action in the brain propose changes along the dorsal-ventral and anterior-posterior axes but neglect to address the lateral axis. This article proposes a novel model of psychedelic action called HEALS (Hemispheric Annealing and Lateralization Under Psychedelics) which involves the reversal of the typical hierarchical relationship between the two hemispheres of the brain. In typical modes of consciousness, the hemispheres act in parallel process with the left predominating. Under psychedelics, as well as in other altered states of consciousness (ASCs), this hierarchy is reversed, with the right hemisphere released from inhibition by the left. In support of this model, the available neuroimaging evidence for lateralization under psychedelics is reviewed. Then, various cognitive and emotional changes observed under psychedelics are contrasted with those same functions in each hemisphere. These include attention; social and emotional intelligence; creativity and insight; and language. The article concludes with a review of laterality in other ASCs, such as meditative and trance states, and suggests that many phenomena associated with psychedelics, and other ASCs, might be explained by an atypical annealing between the hemispheres toward right hemisphere predominance.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"416-430"},"PeriodicalIF":4.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review. 变革的催化剂:裸盖菇素的抗抑郁机制——一项系统综述。
IF 5.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-01-20 DOI: 10.1177/02698811241312866
Joshua Liebnau, Felix Betzler, André Kerber
{"title":"Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.","authors":"Joshua Liebnau, Felix Betzler, André Kerber","doi":"10.1177/02698811241312866","DOIUrl":"10.1177/02698811241312866","url":null,"abstract":"<p><strong>Background: </strong>Recent clinical trials suggest promising antidepressant effects of psilocybin, despite methodological challenges. While various studies have investigated distinct mechanisms and proposed theoretical opinions, a comprehensive understanding of psilocybin's neurobiological and psychological antidepressant mechanisms is lacking.</p><p><strong>Aims: </strong>Systematically review potential antidepressant neurobiological and psychological mechanisms of psilocybin.</p><p><strong>Methods: </strong>Search terms were generated based on existing evidence of psilocybin's effects related to antidepressant mechanisms. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, 15 studies were systematically reviewed, exploring various therapeutic change principles such as brain dynamics, emotion regulation, cognition, self-referential processing, connectedness, and interpersonal functioning.</p><p><strong>Results: </strong>Within a supportive setting, psilocybin promoted openness, cognitive and neural flexibility, and greater ability and acceptance of emotional experiences. A renewed sense of connectedness to the self, others, and the world emerged as a key experience. Imaging studies consistently found altered brain dynamics, characterized by reduced global and within default mode network connectivity, alongside increased between-network connectivity.</p><p><strong>Conclusions: </strong>Together, these changes may create a fertile yet vulnerable window for change, emphasizing the importance of a supportive set, setting, and therapeutic guidance. The results suggest that psilocybin, within a supportive context, may induce antidepressant effects by leveraging the interplay between neurobiological mechanisms and common psychotherapeutic factors. This complements the view of purely pharmacological effects, supporting a multileveled approach that reflects various relevant dimensions of therapeutic change, including neurobiological, psychological, and environmental factors.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"397-415"},"PeriodicalIF":5.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. 单剂量迷幻药治疗酒精使用障碍:一项开放标签研究的药代动力学、可行性、安全性和有效性。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-02-28 DOI: 10.1177/02698811251319457
Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Catharina Dragsted Messell, Emil Deleuran Poulsen, Tibor V Varga, Patrick McDonald Fisher, Marie Katrine Klose Nielsen, Sys Stybe Johansen, Nora D Volkow, Gitte Moos Knudsen, Anders Fink-Jensen
{"title":"Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study.","authors":"Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Catharina Dragsted Messell, Emil Deleuran Poulsen, Tibor V Varga, Patrick McDonald Fisher, Marie Katrine Klose Nielsen, Sys Stybe Johansen, Nora D Volkow, Gitte Moos Knudsen, Anders Fink-Jensen","doi":"10.1177/02698811251319457","DOIUrl":"10.1177/02698811251319457","url":null,"abstract":"<p><strong>Background: </strong>Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of a single dose have not been investigated.</p><p><strong>Aims: </strong>To investigate the pharmacokinetics, feasibility, safety and efficacy of single-dose psilocybin therapy in AUD.</p><p><strong>Methods: </strong>This open-label, single-group study investigated single-dose psilocybin therapy in 10 treatment-seeking adults (8 men and 2 women; median age 44 years) with severe AUD. The treatment involved two preparation sessions, a high-dose psilocybin session (25 mg) and two integration sessions. Pharmacokinetics were determined by noncompartmental analysis, and changes in alcohol consumption, craving and self-efficacy, were assessed using a linear mixed model.</p><p><strong>Results: </strong>Notable between-participant pharmacokinetic variations were observed, with peak plasma psilocin concentrations ranging from 14 to 59 µg/L. Alcohol consumption significantly decreased over the 12 weeks following psilocybin administration. Heavy drinking days were reduced by 37.5 percentage points (95% CI: -61.1 to -13.9, <i>p</i> = 0.005), and drinks per day decreased by 3.4 drinks (95% CI: -6.5 to -0.3, <i>p</i> = 0.03). This was corroborated by reports of rapid and sustained reductions in craving and increases in self-efficacy.</p><p><strong>Conclusions: </strong>Despite pharmacokinetic variations, a single 25 mg psilocybin dose was safe and effective in reducing alcohol consumption in AUD patients. Larger randomised, placebo-controlled, single-dose AUD trials are warranted.</p><p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov/study/NCT04718792.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"463-473"},"PeriodicalIF":4.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics. 余辉量表(AGI):一种用于测量经典色氨酸致幻剂亚急性效应的新仪器的验证。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1177/02698811251326937
Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke, Peter Gasser, William A Richards, Thomas G Riemer, Ricarda Evens
{"title":"The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.","authors":"Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke, Peter Gasser, William A Richards, Thomas G Riemer, Ricarda Evens","doi":"10.1177/02698811251326937","DOIUrl":"10.1177/02698811251326937","url":null,"abstract":"<p><strong>Background: </strong>Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of \"psychedelic afterglow,\" a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute \"afterglow\" effects is needed.</p><p><strong>Aims: </strong>To create and validate a questionnaire to quantify the subacute \"afterglow\" effects of psychedelics.</p><p><strong>Methods: </strong>An international online survey was conducted in English and German. Participants who had consumed a psychedelic (<i>N</i> = 1323) or another non-psychedelic substance (control group, <i>N</i> = 157) within the past 4 weeks were included. An initial list of 97 items was progressively reduced to 24 items.</p><p><strong>Results: </strong>A 5-factor structure best fit the data and showed high internal consistency. The factors included (1) vitality, (2) transpersonal aspects, (3) inspiration/creativity, (4) interpersonal relationships, and (5) relationship to nature. The final 24-item version of the Afterglow Inventory (AGI) effectively differentiated between the psychedelic group and the control group. The overall AGI score positively correlated with the intensity (<i>r</i> = 0.165; <i>p</i> < 0.001) and positive valence (<i>r</i> = 0.251; <i>p</i> < 0.001) of the acute psychedelic effects.</p><p><strong>Conclusions: </strong>The AGI is a novel scale for quantifying positive subacute (\"afterglow\") effects of psychedelics. The use of the AGI could lead to a better understanding of the interplay between acute, subacute, and long-term effects of psychedelics. Insights could also be gained into how different substances, dosages, and extra-pharmacological factors, such as psychotherapy, might influence outcomes.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"474-488"},"PeriodicalIF":4.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data. 勘误:致幻剂的使用与癌症有关吗?用当代人口水平的数据来质疑半个世纪前的说法。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-05-16 DOI: 10.1177/02698811241286656
{"title":"Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data.","authors":"","doi":"10.1177/02698811241286656","DOIUrl":"10.1177/02698811241286656","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"509"},"PeriodicalIF":4.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report. 一项随机、安慰剂对照、双盲、驾驶模拟器和自我报告评估大麻相关驾驶障碍的初步研究。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1177/02698811251324379
Shashwath A Meda, Michael C Stevens, Erwin R Boer, Brian Pittman, Ralitza Gueorguieva, Marilyn A Huestis, Godfrey D Pearlson
{"title":"A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report.","authors":"Shashwath A Meda, Michael C Stevens, Erwin R Boer, Brian Pittman, Ralitza Gueorguieva, Marilyn A Huestis, Godfrey D Pearlson","doi":"10.1177/02698811251324379","DOIUrl":"10.1177/02698811251324379","url":null,"abstract":"<p><strong>Aims: </strong>In the context of increasing cannabis use, understanding how cannabis affects specific driving behaviors is crucial in mitigating risks and ensuring road safety.</p><p><strong>Design and setting: </strong>The current study included 38 adults aged 18-40 years, administered a single 0.5 g acute dose of vaporized cannabis (5.9% Tetrahydrocannabinol (THC), 13% THC or placebo) in a randomized, within-subject, double-blind, counterbalanced design. Throughout each of the three, 8-h assessment days, at 4 time points, participants underwent simulated driving tests, including lane-keeping, car following, and overtaking tasks, capturing 19 behavioral metrics. An SPSS linear mixed model assessed the main effects of dose, time, and dose × time.</p><p><strong>Findings: </strong>During lane-keeping, participants exhibited reduced steering reversal rates up to 5.5 h following 13% THC and 3.5 h for 5.9%. For car following, participants showed reduced pedal peak-to-peak deviation and reversal rates, persisting for 1-3 h post-dose (only at 13% THC). During overtaking, following 13% THC, subjects demonstrated a shorter median gap to passed cars, lower time-to-potential collision, and more time in the oncoming lane. Drug effects on driving metrics improved gradually, to varying degrees over time. Approximately 66% of participants reported willingness to drive, despite subjective awareness of being impaired and objectively worse driving performance.</p><p><strong>Conclusions: </strong>Our study reveals for the first time long-lasting cannabis-induced impairments across multiple driving behaviors, that extend beyond the typical 3-h window explored in most previous research. The observed discrepancy between participants' willingness to drive and their actual impairment highlights an important public safety concern. In addition, the lack of correlation between cannabinoid metabolite concentrations and driving performance challenges the reliability of blood THC levels as impairment indicators, emphasizing the need for a multifaceted approach to assessing cannabis-impaired driving risk.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"364-372"},"PeriodicalIF":4.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study. 死藤水增强海马体依赖性情景记忆的形成,但不影响有经验的死藤水使用者的错误记忆易感性:一项观察性研究。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-04-01 Epub Date: 2024-11-29 DOI: 10.1177/02698811241301216
Manoj K Doss, Lilian Kloft, Natasha L Mason, Pablo Mallaroni, Johannes T Reckweg, Kim van Oorsouw, Nina Tupper, Henry Otgaar, Johannes G Ramaekers
{"title":"Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study.","authors":"Manoj K Doss, Lilian Kloft, Natasha L Mason, Pablo Mallaroni, Johannes T Reckweg, Kim van Oorsouw, Nina Tupper, Henry Otgaar, Johannes G Ramaekers","doi":"10.1177/02698811241301216","DOIUrl":"10.1177/02698811241301216","url":null,"abstract":"<p><strong>Background: </strong>Ayahuasca is an Amazonian brew with 5-HT<sub>2A</sub>-dependent psychedelic effects taken by religious groups globally. Recently, psychedelics have been shown to impair the formation of recollections (hippocampal-dependent episodic memory for specific details) and potentially distort memory while remembering. However, psychedelics spare or enhance the formation of familiarity-based memory (cortical-dependent feeling of knowing that a stimulus has been processed).</p><p><strong>Aims: </strong>Given the growing literature on the plasticity-promoting effects of psychedelics, we investigated the acute impact of ayahuasca on recollection, familiarity, and false memory in an observational study of 24 Santo Daime members with >500 lifetime ayahuasca uses on average.</p><p><strong>Methods: </strong>Participants completed a false memory task at baseline and after they consumed a self-selected dose of ayahuasca prepared by their church (average dose contained 3.36 and 170.64 mg of <i>N,N</i>-dimethyltryptamine and β-carbolines, respectively).</p><p><strong>Results: </strong>Surprisingly, pre-encoding administration of ayahuasca enhanced hit rates, memory accuracy, and recollection but had no impact on familiarity or false memory. Although practice effects cannot be discounted, these memory enhancements were large and selective, as multiple measures of false memory and metamemory did not improve across testing sessions. β-carboline activity potentially accounted for this recollection enhancement that diverges from past psychedelic research. Although ayahuasca did not impact familiarity, these estimates were generally elevated across conditions compared to past work, alluding to a consequence of frequently driving cortical plasticity.</p><p><strong>Conclusions: </strong>When encoding and retrieval took place under acute ayahuasca effects in experienced ayahuasca users, susceptibility to memory distortions did not increase, potentially owing to enhancements in memory accuracy.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"339-349"},"PeriodicalIF":4.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of ashwagandha (Withania somnifera) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study. ashwagandha (Withania somnifera)提取物与Somin-On™改善轻度认知障碍成人记忆的作用:一项随机、双盲、安慰剂对照研究。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-18 DOI: 10.1177/02698811251324377
Hari Prakash Rai, Deo Nidhi Mishra
{"title":"Effect of ashwagandha (<i>Withania somnifera</i>) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study.","authors":"Hari Prakash Rai, Deo Nidhi Mishra","doi":"10.1177/02698811251324377","DOIUrl":"10.1177/02698811251324377","url":null,"abstract":"<p><strong>Background: </strong>Mild cognitive impairment (MCI) is a condition in which people have memory or thinking problems than other people of their age. This study evaluated the effectiveness and safety of ashwagandha extract standardized with Sominone (Somin-On™) in enhancing memory and cognitive functioning in adults with MCI.</p><p><strong>Methods: </strong>In this randomized double-blind, placebo-controlled pilot study, 40 subjects with MCI were randomized in a 1:1 ratio to receive either Somin-On™ (250 mg daily) or a placebo for 60 days. The outcome measures, improvement in memory and other cognitive functions after 30 and 60 days were assessed using Montreal Cognitive Assessment (MoCA); Mini-mental state examination (MMSE); Wechsler Memory Scale-III (WMS-III)); and Shepard mental rotation task.</p><p><strong>Results: </strong>Subjects treated with Somin-On™ showed significant improvements in immediate memory, general memory, working memory and visuospatial processing and the response assessed using WMS-III after 30 and 60 days outperforming the placebo group. Scores on the Shepard Mental Rotation test in Somin-On™ group showed a significant rise by 12.22% at 30 days and 31.67% at 60 days, from baseline. Significant improvement was observed with Somin-On™ in memory assessment scales viz. MoCA (7.83% at 30 days and 14.77% at 60 days, from baseline) and MMSE (9.26% at 30 days and 19.21% at 60 days, from baseline) compared to placebo group.</p><p><strong>Conclusions: </strong>The supplementation of Somin-On™ is an effective therapy to improve the immediate, general and working memory, as well as cognitive functions like attention and information processing speed in adults with MCI.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"350-363"},"PeriodicalIF":4.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions. 开展实验调查的三阶段策略:提高报告结论可重复性的建议。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1177/02698811251319453
Simon T Bate, S Clare Stanford, Lee Page
{"title":"A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions.","authors":"Simon T Bate, S Clare Stanford, Lee Page","doi":"10.1177/02698811251319453","DOIUrl":"10.1177/02698811251319453","url":null,"abstract":"<p><p>The reproducibility of the results from preclinical research rests on many factors, including the selection of appropriate experimental designs for the individual experiments that constitute the investigation. The design of each of these experiments depends on their purpose within the entire investigation and the information to be gained from conducting them. Here, we explain and justify a three-stage strategy comprising a series of different types of experiment, each with a different purpose and design: a pilot study, a hypothesis-generating experiment and a final hypothesis-confirming experiment. Compliance with this three-stage strategy, over the course of an entire investigation, will not only strengthen its reproducibility but, importantly, can save time and other resources, including the total number of animals used.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"301-312"},"PeriodicalIF":4.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The relationship between Parkinson's disease and sexual hyperactivity secondary to drug treatment: A systematic review. 帕金森病与继发于药物治疗的性亢进之间的关系:系统综述。
IF 4.5 3区 医学
Journal of Psychopharmacology Pub Date : 2025-04-01 Epub Date: 2024-09-16 DOI: 10.1177/02698811241277200
Verónica Aparicio-López, María Rueda-Extremera, María Cantero-García
{"title":"The relationship between Parkinson's disease and sexual hyperactivity secondary to drug treatment: A systematic review.","authors":"Verónica Aparicio-López, María Rueda-Extremera, María Cantero-García","doi":"10.1177/02698811241277200","DOIUrl":"10.1177/02698811241277200","url":null,"abstract":"<p><strong>Introduction: </strong>This review addresses the prevalence of hypersexual behavior in Parkinson's patients and the underlying neurobiological mechanisms, identifying risk and protective factors, comparing incidence among different treatments, and proposing recommendations for management and prevention.</p><p><strong>Objective: </strong>To conduct a review on the relationship between Parkinson's disease and hypersexual behavior as a result of pharmacological treatment.</p><p><strong>Methodology: </strong>The search strategy, guided by PRISMA and PICOS criteria, focuses on the correlation between Parkinson's disease and hypersexual behavior due to pharmacological treatment. Utilizing databases like PubMed and Proquest, studies from the last 10 years in English or Spanish were selected, emphasizing clinical trials with Parkinson's patients under treatment. Inaccessible, irrelevant, or mixed-sample studies were excluded. The Cochrane Scale assessed the risk of bias.</p><p><strong>Results: </strong>Out of 122 records, 103 remained after eliminating duplicates; 48 were reviewed, and ultimately, 6 studies met the inclusion criteria for analysis.</p><p><strong>Conclusions: </strong>Synthesizing the risk and protective factors linked to hypersexual behavior in Parkinson's patients receiving pharmacological treatment underscores the critical need for early detection and incorporation of these factors into clinical care. The suggested guidelines for managing and preventing hypersexual behavior in these patients carry substantial practical implications.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"316-327"},"PeriodicalIF":4.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信